Novartis scores 21 points higher than Bayer on SINK.
Novartis is more sustainable according to SINK's scores, scoring 52/100 vs Bayer's 31/100, a difference of 21 points.
Bayer scores 31/100 on SINK (Below expectations). Bayer reports comprehensive climate data with 21.9% Scope 1&2 reductions and SBTi-validated targets, but faces systematic controversies: 170,000+ Roundup lawsuits, $11B settlements, an OECD deforestation complaint, and glyphosate biodiversity damage. Emissions trajectory is inconsistent, Scope 3 gaps remain, and reliance on offsets undermines net-zero credibility.
Novartis scores 52/100 on SINK (Making progress). Novartis cut its emissions to 4.36 MtCO2e in 2025, with Scope 1 and 2 down 45% and Scope 3 down 17% against 2022, under SBTi-validated targets for net zero by 2040. Its electricity is 100% renewable, though only 49% of all its energy is. Its waste rose in 2025, its 'carbon neutral' claim rests on removal credits and certificates, and old chemical landfills near Basel are still being cleaned up.
Both companies are rated on the same 10-question SINK rubric: Scope 1/2/3 carbon footprint, energy source, nature and biodiversity, resource use, water, emissions trajectory, science-based targets, transparency, and controversies. Scores are 0–100, based on public data, and fully reproducible.
See the full leaderboard: 1,023 companies ranked.
View the full leaderboard →